文献速递呼吸道感染呼吸危重症与机械通气

COVID-19患者呼吸机相关性肺炎的归因死亡率

Attributable Mortality of Ventilator-associated Pneumonia Among Patients with COVID-19.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

基于REA-REZO监测网络,比较2016-2019年对照患者、2020年非COVID-19大流行患者及COVID-19大流行患者的VAP归因死亡率。COVID-19患者VAP发生率31.9/1000通气日,90天归因死亡率8.13%,归因分数9.17%。

要点

  • COVID-19患者VAP发生率31.9/1000通气日,高于对照组的14.2。
  • COVID-19患者VAP 90天归因死亡率为8.13%,总体死亡中超过9%归因于VAP。
  • 非COVID-19大流行患者VAP归因死亡率与对照组相似。

核心结论

  • COVID-19患者VAP归因死亡率更高,超过9%的总体死亡与VAP相关。

研究设计与样本

  • 多中心监测网络回顾性队列,纳入成人内科ICU患者共64816例对照组、7442例非COVID-19大流行组和1687例COVID-19大流行组。

主要发现

  • VAP发生率分别为对照组14.2(95%CI 13.9-14.6)、非COVID-19组18.3(95%CI 17.3-19.4)、COVID-19组31.9(95%CI 29.8-34.2)/1000通气日。
  • 90天归因死亡率分别为对照组3.15%(95%CI 2.04%-3.43%)、非COVID-19组2.91%(95%CI -0.21%-5.02%)、COVID-19组8.13%(95%CI 3.54%-12.24%)。
  • 90天归因分数分别为对照组1.22%(95%CI 0.83-1.63)、非COVID-19组1.42%(95%CI -0.11%-2.61%)、COVID-19组9.17%(95%CI 3.54%-12.24%)。
  • COVID-19患者无VAP时死亡风险低于对照组(HR 0.62,95%CI 0.52-0.74)。

临床怎么用

  • 对COVID-19机械通气患者应加强VAP预防,因其归因死亡率显著更高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Patients with a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are at higher risk of ventilator-associated pneumonia (VAP) and may have an increased attributable mortality (increased or decreased risk of death if VAP occurs in a patient) and attributable fraction (proportion of deaths that are attributable to an exposure) of VAP-related mortality compared with subjects without coronavirus disease (COVID-19). Objectives: Estimation of the attributable mortality of the VAP among patients with COVID-19. Methods: Using the REA-REZO surveillance network, three groups of adult medical ICU patients were computed: control group (patients admitted between 2016 and 2019; prepandemic patients), pandemic COVID-19 group (PandeCOV+), and pandemic non-COVID-19 group (PandeCOV-) admitted during 2020. The primary outcome was the estimation of attributable mortality and attributable fraction related to VAP in these patients. Using multistate modeling with causal inference, the outcomes related to VAP were also evaluated. Measurements and Main Results: A total of 64,816 patients were included in the control group, 7,442 in the PandeCOV- group, and 1,687 in the PandeCOV+ group. The incidence of VAP was 14.2 (95% confidence interval [CI], 13.9 to 14.6), 18.3 (95% CI, 17.3 to 19.4), and 31.9 (95% CI, 29.8 to 34.2) per 1,000 ventilation-days in each group, respectively. Attributable mortality at 90 days was 3.15% (95%, CI, 2.04% to 3.43%), 2.91% (95% CI, -0.21% to 5.02%), and 8.13% (95% CI, 3.54% to 12.24%), and attributable fraction of mortality at 90 days was 1.22% (95% CI, 0.83 to 1.63), 1.42% (95% CI, -0.11% to 2.61%), and 9.17% (95% CI, 3.54% to 12.24%) for the control, PandeCOV-, and PandeCOV+ groups, respectively. Except for the higher risk of developing VAP, the PandeCOV- group shared similar VAP characteristics with the control group. PandeCOV+ patients were at lower risk of death without VAP (hazard ratio, 0.62; 95% CI, 0.52 to 0.74) than the control group. Conclusions: VAP-attributable mortality was higher for patients with COVID-19, with more than 9% of the overall mortality related to VAP.

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Vacheron CH, Lepape A, Savey A, et al. Attributable Mortality of Ventilator-associated Pneumonia Among Patients with COVID-19. Am J Respir Crit Care Med. 2022. PMID: 35537122. doi:10.1164/rccm.202202-0357OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。